Daily Oral Drug Produced Significant Weight Loss in Lilly Obesity Trial
In a 36-week phase 2 trial, Eli Lilly’s investigational oral GLP-1 medicine orforglipron helped adults with obesity or overweight lose more weight on average than participants taking placebo. Digestive side…